Art. -Nr.: HY-15459

Cabazitaxel

(Synonyms: XRP6258; RPR-116258A; taxoid XRP6258)

26 Cited Publications

Kundenbewertung

Based on 26 publication(s) in Google Scholar

Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.98%
CAS. Nr.: 183133-96-2
Formel: C₄₅H₅₇NO₁₄
Molecular Weight:835.93

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Cabazitaxel Chemical Structure

CAS. Nr.: 183133-96-2

Größe

Preis

Verfügbarkeit

Menge

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Angebot einholen Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Massenanfrage

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (26)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	GI₅₀	1.483 nM Compound: 3	Growth inhibition of human A431 cells by MTT assay Growth inhibition of human A431 cells by MTT assay	[PMID: 24405702]
A549	GI₅₀	1.483 nM Compound: 3	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 24405702]
A549	IC₅₀	1.48 nM Compound: 9	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 28850227]
A549	IC₅₀	15 nM Compound: Cabazitaxel	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34058663]
A549/TR	IC₅₀	62.5 nM Compound: Cabazitaxel	Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34058663]
BGC-823	GI₅₀	467.2 nM Compound: 3	Growth inhibition of human BGC823 cells by MTT assay Growth inhibition of human BGC823 cells by MTT assay	[PMID: 24405702]
DU-145	GI₅₀	1.429 nM Compound: 3	Growth inhibition of human DU145 cells by MTT assay Growth inhibition of human DU145 cells by MTT assay	[PMID: 24405702]
HCT-116	IC₅₀	0.029 μM Compound: 22; CBT	Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay	[PMID: 38142509]
HCT-8	IC₅₀	0.532 μM Compound: 22; CBT	Antiproliferative activity against human HCT-8 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-8 cells measured after 48 hrs by MTT assay	[PMID: 38142509]
HeLa	GI₅₀	1.799 nM Compound: 3	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 24405702]
HL-60	GI₅₀	4.736 nM Compound: 3	Growth inhibition of human HL60 cells by MTT assay Growth inhibition of human HL60 cells by MTT assay	[PMID: 24405702]
HT-1080	GI₅₀	1.406 nM Compound: 3	Growth inhibition of human HT1080 cells by MTT assay Growth inhibition of human HT1080 cells by MTT assay	[PMID: 24405702]
K562	GI₅₀	4.186 nM Compound: 3	Growth inhibition of human K562 cells by MTT assay Growth inhibition of human K562 cells by MTT assay	[PMID: 24405702]
KB	IC₅₀	20 nM Compound: Cabazitaxel	Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34058663]
LoVo	IC₅₀	0.063 μM Compound: 22; CBT	Antiproliferative activity against human LoVo cells measured after 48 hrs by MTT assay Antiproliferative activity against human LoVo cells measured after 48 hrs by MTT assay	[PMID: 38142509]
MCF7	GI₅₀	1.187 nM Compound: 3	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 24405702]
MES-SA/Dx5	IC₅₀	15 nM Compound: Cabazitaxel	Growth inhibition of human MES-SA/Dx5 cells after 72 hrs by SRB assay Growth inhibition of human MES-SA/Dx5 cells after 72 hrs by SRB assay	[PMID: 29251920]
NCI-H524	IC₅₀	0.26 nM Compound: Cabazitaxel	Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay	[PMID: 30735385]
PANC-1	GI₅₀	1.283 nM Compound: 3	Growth inhibition of human PANC1 cells by MTT assay Growth inhibition of human PANC1 cells by MTT assay	[PMID: 24405702]
SGC-7901	GI₅₀	0.3553 nM Compound: 3	Growth inhibition of human SGC7901 cells by MTT assay Growth inhibition of human SGC7901 cells by MTT assay	[PMID: 24405702]
U-937	GI₅₀	0.5391 nM Compound: 3	Growth inhibition of human U937 cells by MTT assay Growth inhibition of human U937 cells by MTT assay	[PMID: 24405702]

In Vitro

The cytotoxicity of cabazitaxel (100 μg/mL) on 4T1 cells without irradiation is 70.8%. Cabazitaxel (100 μg/mL) exhibits a concentration-dependent antiproliferation effect, with the antiproliferative activity of 56.2%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cabazitaxel (10 mg/kg, i.v.) has certain toxicity to liver and kidney but it can be avoided by integrated into Ans. The body weights of mice treated with AN-ICG-CBX and AN-CBX have a slightly decrease, while body weights of the free CBX group significantly decrease compared to the control group^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 183133-96-2
Appearance Solid
Molecular Weight 835.93
Formel C₄₅H₅₇NO₁₄
Color White to off-white
SMILES

CC1=C([C@@H](OC)C([C@@]2(C)[C@@]3([H])[C@](OC(C)=O)(CO4)[C@H]4C[C@@H]2OC)=O)C(C)(C)[C@@]([C@H]3OC(C5=CC=CC=C5)=O)(O)C[C@@H]1OC([C@H](O)[C@H](C6=CC=CC=C6)NC(OC(C)(C)C)=O)=O
Synonyms

XRP6258; RPR-116258A; taxoid XRP6258
Structure Classification
- Others
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (26)

All Cell Proliferation/Viability AssayCell Imaging/StainingWBCell Migration/Invasion AssayELISA

Sort by:

Journal Impact Factor

Eur Urol

Taxane-induced Attenuation of the CXCR2/BCL-2 Axis Sensitizes Prostate Cancer to Platinum-based Treatment. [Abstract]

2020 Nov 2;S0302-2838(20)30778-8. PMID: 33153817
J Clin Invest

Targeting Wnt/β-Catenin and circadian regulator restores PRC2/EZH2 controlled chromatin bivalency and suppresses cell state diversity. [Abstract]

2026 Mar 17:e200260. PMID: 41842971
Cell Rep Med

CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]

2025 Apr 2:102053. PMID: 40187357
Proc Natl Acad Sci U S A

Chlamydomonas protein kinase MAK phosphorylates FAP256/CEP104 and regulates axonemal microtubule assembly. [Abstract]

2025 Nov 18;122(46):e2503094122. PMID: 41231942

Cabazitaxel purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2025 Nov 18;122(46):e2503094122. [Abstract]

Cabazitaxel (25 μM; 8 h) treatment partially rescues the ciliary phenotype of mak-1. Shown are DIC images of mak-1 cells after treatment with Cabazitaxel.
Pharmaceutics

Cabazitaxel-Loaded Nanoparticles Reduce the Invasiveness in Metastatic Prostate Cancer Cells: Beyond the Classical Taxane Function. [Abstract]

2023 Feb 16;15(2):662. PMID: 36839985

Cabazitaxel purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2023 Feb 16;15(2):662. [Abstract]

Cell viability in C4-2B cell line. The 48 h IC₅₀ values in C4-2B cells are as follows: Cabazitaxel (CBZ), 2.8 nM; NT CBZ NP, 24.5 nM; T CBZ NP, 10.52 nM. The 72 h IC₅₀ values are: CBZ, 4.96; NT CBZ NP, 1.81 nM; T CBZ NP, 5.21 nM (95% confidence intervals (CI)); n = 3.

Cabazitaxel purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2023 Feb 16;15(2):662. [Abstract]

Transwell Invasion Assay indicated that cell invasion was limited with Cabazitaxel (CBZ, 2.5 nM) and CBZ NP with respect to control after 24 h of treatment.

Cabazitaxel purchased from MedChemExpress. Usage Cited in: Pharmaceutics. 2023 Feb 16;15(2):662. [Abstract]

IL-8 mRNA expression was lower in Cabazitaxel (CBZ) and CBZ-loaded NPs at sub-IC₅₀ (2.5 nM; 6 h) concentrations compared to control.
ACS Appl Nano Mater

Bioinspired Nanoparticles Engineered for Enhanced Delivery to the Bone. [Abstract]

2019 Oct 25;2(10):6249-6257. PMID: 33585803

Cabazitaxel purchased from MedChemExpress. Usage Cited in: ACS Appl Nano Mater. 2019 Oct 25;2(10):6249-6257. [Abstract]

MTT cell viability assay after treatment with increasing concentrations (0.2–20.0 μg/mL Cabazitaxel loaded) of BiNP or P-BiNP resulting in decreased cell viability of P-BiNPs at equivalent treatment dosage as BiNPs after 72 h.
Microchem J

2025 Oct 15;218:115702.
RSC Adv

Three-in-one: exploration of co-encapsulation of cabazitaxel, bicalutamide and chlorin e6 in new mixed cyclodextrin-crosslinked polymers. [Abstract]

2023 Apr 6;13(16):10923-10939. PMID: 37033421
Nanomedicine (Lond)

Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. [Abstract]

2017 Sep;12(17):2083-2095. PMID: 28805551
Cell Rep Methods

RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]

2023 Oct 23;3(10):100599. PMID: 37797618
Mol Pharm

Machine Learning Models Identify New Inhibitors for Human OATP1B1. [Abstract]

2022 Nov 7;19(11):4320-4332. PMID: 36269563
Sci Rep

Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening. [Abstract]

2023 Jun 3;13(1):9043. PMID: 37270558
J Pharm Sci

Insights into interactions between taxanes and P-glycoprotein using biophysical and in silico methods. [Abstract]

2025 May;114(5):103708. PMID: 40015511
Cardiovasc Toxicol

The Potential Protective Effects of Resveratrol Against Cabazitaxel-Induced Oxidative Stress and Cardiotoxicity in Rats. [Abstract]

2026 May 27;26(6):61. PMID: 42192024
Bioengineering (Basel)

Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]

2025 Oct 19;12(10):1121. PMID: 41155119
Cancer Manag Res

Antitumor Activity of Cabazitaxel and MSC-TRAIL Derived Extracellular Vesicles in Drug-Resistant Oral Squamous Cell Carcinoma. [Abstract]

2020 Oct 29;12:10809-10820. PMID: 33149686
PLoS One

The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells. [Abstract]

2020 Jun 2;15(6):e0234078. PMID: 32484838
Prostate

Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity. [Abstract]

2018 Sep;78(12):905-914. PMID: 29749077
Prostate

GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling. [Abstract]

2018 Feb;78(3):166-177. PMID: 29181846

Cabazitaxel purchased from MedChemExpress. Usage Cited in: Prostate. 2018 Feb;78(3):166-177. [Abstract]

Western blot analysis of apoptosis marker PARP in stable cell lines treated with 50 or 100 nM Cabazitaxel.
bioRxiv

2026 Mar 18.
bioRxiv

2026 Jan 19.
Patent

US20220211630A1.
Patent

US20220008350A1.
Methods Mol Biol

Methods for High-throughput Drug Combination Screening and Synergy Scoring. [Abstract]

2018:1711:351-398. PMID: 29344898
Oncotarget

Brachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer. [Abstract]

2016 May 17;7(20):28891-902. PMID: 27049720

Cabazitaxel purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 May 17;7(20):28891-902. [Abstract]

Western blot analyses for Brachyury and AR expression in prostate cell lines treated with Docetaxel (Doc) or with Cabazitaxel (Cab). Graphs represent the densimetric semi-quantification of western blot images.
Chin J Cancer

ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel. [Abstract]

2015 Mar 5;34(3):115-20. PMID: 25962593

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (119.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.1963 mL

5.9814 mL

11.9627 mL

5 mM

0.2393 mL

1.1963 mL

2.3925 mL

10 mM

0.1196 mL

0.5981 mL

1.1963 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

The cytotoxicity of CBX-loaded ANs and free Cabazitaxel (CBX) is evaluated with MTT assay. Cells are seeded onto a 96-well plate at a density of 3000 cells per well and cultured for 24 h. CBX-loaded ANs and free CBX are diluted to predetermined concentrations with PBS and added into each well. Blank AN, AN-ICG and free CBX solvent (a mixture of Tween-80 and anhydrous alcohol) are added as well to different final concentrations. The incubation continued for another 48 hours. 20 µL MTT solutions (5 mg/mL in PBS) are added into each well and cells are incubated for another 4 hours under 37°C. Subsequently the medium is removed and 150 µL dimethyl sulphoxide (DMSO) is added to dissolve the purple formazan salt crystals. Then the absorbance is measured by a microplate reader at 490 nm. The cells treated with medium are evaluated as controls.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

To evaluate the antitumor efficiency of the combined chemotherapy and PTT in vivo, mice bearing 4T1 tumor are randomLy divided into 6 treatment groups (n=5). Treatment begin when the tumors reached 50 mm³-100 mm³. The mice are intravenously injected with saline, AN-ICG, free Cabazitaxel (CBX), AN-CBX and AN-ICG-CBX (ICG 2 mg/kg, CBX 10 mg/kg). 8 hours later, the groups injected with AN-ICG and AN-ICG-CBX is irradiated by the 808 nm laser (0.8 W/cm², 5 min). The length and width of every tumor are measured by a caliper every other day. The formula (volume (mm³) =1/2 × length × width²) is used to calculate the tumor volume. The body weights of these mice are recorded every two days using an electronic balance as well. At the end of the antitumor study, the 4T1 tumor bearing mice are sacrificed to collect the tumors and major organs.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (557 KB)
- English - EN (557 KB)
- Français - FR (557 KB)
- Deutsch - DE (557 KB)
- Norwegian - NO (557 KB)
- Español - ES (557 KB)
- Swedish - SV (557 KB)
- Italian - IT (557 KB)
- Portuguese - PT (557 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Tai X, et al. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J Drug Target. 2016 Sep 9:1-29. [Content Brief]

[2]. Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond). 2017 Sep;12(17):2083-2095. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.1963 mL	5.9814 mL	11.9627 mL	29.9068 mL
	5 mM	0.2393 mL	1.1963 mL	2.3925 mL	5.9814 mL
	10 mM	0.1196 mL	0.5981 mL	1.1963 mL	2.9907 mL
	15 mM	0.0798 mL	0.3988 mL	0.7975 mL	1.9938 mL
	20 mM	0.0598 mL	0.2991 mL	0.5981 mL	1.4953 mL
	25 mM	0.0479 mL	0.2393 mL	0.4785 mL	1.1963 mL
	30 mM	0.0399 mL	0.1994 mL	0.3988 mL	0.9969 mL
	40 mM	0.0299 mL	0.1495 mL	0.2991 mL	0.7477 mL
	50 mM	0.0239 mL	0.1196 mL	0.2393 mL	0.5981 mL
	60 mM	0.0199 mL	0.0997 mL	0.1994 mL	0.4984 mL
	80 mM	0.0150 mL	0.0748 mL	0.1495 mL	0.3738 mL
	100 mM	0.0120 mL	0.0598 mL	0.1196 mL	0.2991 mL

Keywords

Cabazitaxel

26 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Cabazitaxel

Cell Cycle/DNA Damage Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Macrocyclic Compound Library

Cytoskeleton Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Therapy Drug Library

Anti-Cancer Natural Product Library

Protein-protein Interaction Inhibitor Library

Chemotherapy Drug Library

Plant-Sourced Natural Product Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Cell Death Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Cancer Approved Drug Library

Mass Spectrometry Human Metabolite Library

High-Efficiency Gene Editing Compound Library

Natural Product Diversity Scaffold Library

Classic FDA-Approved Drug Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Cabazitaxel

Biologische Aktivität

Chemical Information

Publications (26)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Cabazitaxel Related Classifications

Art. -Nr.: HY-15459